How Small Biotechs Navigate Clinical Trial Vendor Oversight
At SCOPE Europe 2025, a panel on vendor identification, selection, and management highlighted a pragmatic blueprint for small biopharma:...
Shining Light on Women’s Health: A New Non-Drug Vaginal Therapy
In this interview, I spoke with Dr. Melanie Santos, Chief Medical Officer at Cern Corporation, about a novel low...
New Analysis Supports Genetic Tool for Depression Treatment
In a retrospective re-analysis of Sanofi’s prior Phase 2 Major Depressive Disorder study (NCT00358631), patients receiving the vasopressin V1b...
Cidara Presents Late-Breaking Phase 2 CD388 Clinical Data
Cidara will deliver late-breaking Phase 2 data for its long-acting influenza prophylactic CD388 at ID Week on October 20,...
4DMT’s CF Drug Advances to Phase 2 with Foundation Support
Enrollment is underway in the Phase 2 stage of 4D Molecular Therapeutics’ AEROW trial with 2.5E14 vg set as...
Hutchmed to Present FRUSICA-2 Trial Data at ESMO Congress
Topline: In the Phase III FRUSICA-2 study (n=234) in second-line advanced renal cell carcinoma, fruquintinib plus sintilimab achieved a...
AdvanCell’s New Alpha Therapy Shows Promise for Prostate Cancer
AdvanCell’s ESMO abstract reports favorable safety and early anti-tumor activity for ADVC001, a Lead-212 (212Pb)-labeled PSMA radioligand, across seven...
The Human Cost of Fragmented Technology: A Conversation with Veeva’s Bree Burks
At the Veeva R&D and Quality Summit in Boston, we spoke with Bree Burks, Vice President of Strategy at...
Brepocitinib Poised to Fill Dermatomyositis Treatment Gap
The Phase 3 VALOR trial of brepocitinib in dermatomyositis has completed enrollment and is powered on the Total Improvement...
Assembly Bio Presents Interim Data on HSV Inhibitor ABI-5366
Interim Phase 1b data for Assembly Bio’s oral helicase-primase inhibitor ABI-5366 showed statistically significant reductions in key virologic and...